Research ArticleRheumatoid Arthritis

Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals

Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Bart J.F. van den Bemt, Michael T. Nurmohamed, Martijn B.A. van Doorn, Phyllis I. Spuls, Astrid M. van Tubergen, Peter M. ten Klooster, Eugene P. van Puijenbroek, Frank Hoentjen and Harald E. Vonkeman
The Journal of Rheumatology September 2021, 48 (9) 1388-1394; DOI: https://doi.org/10.3899/jrheum.201373

REFERENCES

  1. 1.↵
    1. Tank ND,
    2. Karelia BN,
    3. Vegada BN
    . Biological response modifiers in rheumatoid arthritis: systematic review and meta-analysis of safety. J Pharmacol Pharmacother 2017;8:92-105.
    OpenUrl
  2. 2.↵
    1. European Medicines Agency
    . Enbrel product information. [Internet. Accessed May 12, 2021.] Available from: www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf
  3. 3.↵
    1. European Medicines Agency
    . Remicade product information. [Internet. Accessed May 12, 2021.] Available from: www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf
  4. 4.↵
    1. European Medicines Agency
    . Humira product information. [10-01-2020; cited 14-4-2020]; Available from: www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf
  5. 5.↵
    1. Verazza S,
    2. Davì S,
    3. Consolaro A,
    4. Bovis F,
    5. Insalaco A,
    6. Magni-Manzoni S, et al; Italian Pediatric Rheumatology Study Group
    . Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol Online J 2016;14:68.
    OpenUrl
  6. 6.↵
    1. Hutchings D,
    2. Miller JA,
    3. Voltaggio L
    . Paradoxical gastrointestinal reactions in patients taking tumor necrosis factor inhibitors: a rare event that broadens the histologic spectrum of medication-associated injury. Hum Pathol 2019;85:202-9.
    OpenUrl
  7. 7.↵
    1. Forouzandeh M,
    2. Vazquez T,
    3. Nouri K,
    4. Forouzandeh B
    . The paradoxical induction of Crohn’s disease following treatment of psoriatic arthritis with etanercept. J Drug Dermatol 2019;18:832-4.
    OpenUrl
  8. 8.
    1. Tolu S,
    2. Rezvani A,
    3. Hindioglu N,
    4. Calkin Korkmaz M
    . Etanercept-induced Crohn’s disease in ankylosing spondylitis: a case report and review of the literature. Rheumatol Int 2018;38:2157-62.
    OpenUrl
  9. 9.
    1. Flemming GM,
    2. Tóth G,
    3. Gebauer C,
    4. Schuster V
    . Crohn’s disease in a patient with juvenile idiopathic arthritis after starting etanercept therapy - causal link or only temporal coincidence? Klin Padiatr 2013;225:350-1.
    OpenUrl
  10. 10.
    1. Wiegering V,
    2. Morbach H,
    3. Dick A,
    4. Girschick HJ
    . Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int 2010;30:801-4.
    OpenUrlCrossRefPubMed
  11. 11.
    1. Yazisiz V,
    2. Avci AB,
    3. Erbasan F,
    4. Yildirim B,
    5. Terzioğlu E
    . Development of Crohn’s disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis 2008;10:953-4.
    OpenUrlPubMed
  12. 12.↵
    1. Dallocchio A,
    2. Canioni D,
    3. Ruemmele F,
    4. Duquesne A,
    5. Scoazec JY,
    6. Bouvier R, et al; SOFREMIP
    . Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology 2010;49:1694-8.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. van Lint JA,
    2. Jessurun N,
    3. Hebing RCF,
    4. Hoentjen F,
    5. Tas SW,
    6. Vonkeman HE, et al.
    Patient-reported burden of adverse drug reactions attributed to biologics used for immune-mediated inflammatory diseases. Drug Saf 2020;43:917-25.
    OpenUrl
  14. 14.↵
    1. Basch E
    . Systematic collection of patient-reported adverse drug reactions: a path to patient-centred pharmacovigilance. Drug Saf 2013;36:277-8.
    OpenUrl
  15. 15.↵
    1. Kosse LJ,
    2. Jessurun N,
    3. Hebing RCF,
    4. Huiskes VJB,
    5. Spijkers KM,
    6. van den Bemt BJF, et al.
    Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatology 2020;59:1253-61.
    OpenUrl
  16. 16.↵
    1. Kievit W,
    2. Fransen J,
    3. Adang EM,
    4. den Broeder AA,
    5. Bernelot Moens HJ,
    6. Visser H, et al.
    Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology 2011;50:196-203.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Webers C,
    2. Beckers E,
    3. Boonen A,
    4. van Eijk-Hustings Y,
    5. Vonkeman H,
    6. van de Laar M, et al.
    Development, usability and acceptability of an integrated eHealth system for spondyloarthritis in the Netherlands (SpA-Net). RMD Open 2019;5:e000860.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Giraud EL,
    2. Jessurun NT,
    3. van Hunsel FPAM,
    4. van Puijenbroek EP,
    5. van Tubergen A,
    6. ten Klooster PM, et al.
    Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. Expert Opin Drug Saf 2020;19:1617-24.
    OpenUrl
  19. 19.↵
    1. DREAM-RA registry
    . [Internet. Accessed May 12, 2021.] Available from: www.dreamregistry.nl
  20. 20.↵
    1. Kievit W,
    2. Fransen J,
    3. Oerlemans AJ,
    4. Kuper HH,
    5. van der Laar MA,
    6. de Rooij DJ, et al.
    The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-8.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Vermeer M,
    2. Kuper HH,
    3. Hoekstra M,
    4. Haagsma CJ,
    5. Posthumus MD,
    6. Brus HL, et al.
    Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011;63:2865-72.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Steunebrink LM,
    2. Versteeg GA,
    3. Vonkeman HE,
    4. ten Klooster PM,
    5. Kuper HH,
    6. Zijlstra TR, et al.
    Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. Arthritis Res Ther 2016;18:60.
    OpenUrl
  23. 23.↵
    1. Bankowski Z,
    2. Bruppacher R,
    3. Crusius I,
    4. Gallagher J,
    5. Kremer G,
    6. Venulet J
    , editors. Reporting adverse drug reactions: definition of terms and criteria for their use. Council International Organizations of Medical Sciences (CIOMS). [Internet. Accessed May 12, 2021.] Available from: cioms.ch/wp-content/uploads/2017/01/reporting_adverse_drug.pdf
  24. 24.↵
    1. Medical Dictionary for Regulatory Activities
    . [Internet. Accessed May 12, 2021.] Available from: www.meddra.org
  25. 25.↵
    1. Naranjo CA,
    2. Busto U,
    3. Sellers EM,
    4. Sandor P,
    5. Ruiz I,
    6. Roberts EA, et al.
    A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Haraoui B,
    2. Krelenbaum M
    . Emergence of Crohn’s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 2009;39:176-81.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Bieber A,
    2. Fawaz A,
    3. Novofastovski I,
    4. Mader R
    . Antitumor necrosis factor-α therapy associated with inflammatory bowel disease: three cases and a systematic literature review. J Rheumatol 2017; 44:1088-95.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Picchianti-Diamanti A,
    2. Panebianco C,
    3. Salemi S,
    4. Sorgi ML,
    5. Di Rosa R,
    6. Tropea A, et al.
    Analysis of gut microbiota in rheumatoid arthritis patients: disease-related dysbiosis and modifications induced by etanercept. Int J Mol Sci 2018;19:2938.
    OpenUrlPubMed
  29. 29.↵
    1. Dubeau MF,
    2. Iacucci M,
    3. Beck PL,
    4. Moran GW,
    5. Kaplan GG,
    6. Ghosh S, et al.
    Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis 2013;19:445-56.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Korzenik J,
    2. Larsen MD,
    3. Nielsen J,
    4. Kjeldsen J,
    5. Nørgård BM
    . Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:289-94.
    OpenUrl
  31. 31.↵
    1. Barthel D,
    2. Ganser G,
    3. Kuester RM,
    4. Onken N,
    5. Minden K,
    6. Girschick HJ, et al.
    Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol 2015;42:2160-5.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Craig E,
    2. Cappelli LC
    . Gastrointestinal and hepatic disease in rheumatoid arthritis. Rheum Dis Clin North Am 2018;44:89-111.
    OpenUrl
  33. 33.↵
    1. Wood PR,
    2. Caplan L
    . Drug-induced gastrointestinal and hepatic disease associated with biologics and nonbiologic disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 2018;44:29-43.
    OpenUrl
  34. 34.↵
    1. Solomon DH,
    2. Glynn RJ,
    3. Karlson EW,
    4. Lu F,
    5. Corrigan C,
    6. Colls J, et al.
    Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med 2020;172:369-80.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

adverse drug reactions
BIOLOGICAL THERAPY
drug monitoring
DRUG SAFETY
REGISTRIES

Keywords